NCT04296175View on ClinicalTrials.gov

Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

808

Participants

Timeline

Start Date

March 5, 2020

Primary Completion Date

March 10, 2025

Study Completion Date

March 31, 2027

Conditions
Triple-negative Breast Cancer
Interventions
DRUG

Epirubicin

90mg/m2, d1 every 2 or 3 weeks

DRUG

CTX

600mg, d1 every 2 or 3 weeks

DRUG

Paclitaxel

80mg/m2,d1,d8,d15, every 3 weeks

DRUG

ddEpirubicin

90mg/m2, d1 every 2 weeks

DRUG

ddCTX

600mg, d1 every 2 weeks

DRUG

Paclitaxel(with carbo)

80mg/m2,d1,d8,d15, every 4 weeks

DRUG

Carboplatin

AUC=2,d1,d8,d15, every 4 weeks

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER